Venture-backed Epirus sees positive data of Remicade biosimilar

 
(Ref: Boston Business Journal)
  • Epirus Biopharmaceuticals, formerly called fourteen22, reported positive Phase I data of BOW-015, a biosimilar to Remicade, Boston Business Journal reported on Wednesday.
  • The drug is a monoclonal antibody against tumour necrosis factor alpha used to treat autoimmune diseases.